HBV相关肝细胞癌的炎症机制及调控因素研究进展

摘要/Abstract

摘要： 慢性乙型肝炎病毒(HBV)感染是全球重大公共卫生问题,其核心病理特征为肝脏迁延不愈的慢性炎症,导致持续的肝细胞炎性坏死,进入代偿性再生循环,进而导致肝纤维化、肝硬化乃至肝细胞癌(HCC)的发生、发展。慢性乙型肝炎的疾病进展是病毒与宿主互作、共同参与的复杂过程。本文系统综述HBV相关HCC的核心病理过程及影响因素,以期为优化慢性乙型肝炎临床诊疗、降低HCC发生风险提供参考。

关键词: 乙型肝炎病毒, 肝脏炎症, 肝细胞癌, 免疫调节

刘新, 雷启琴, 鲁凤民. HBV相关肝细胞癌的炎症机制及调控因素研究进展[J]. 肝脏, 2026, 31(7): 927-931.

/ 推荐

[1] Yan R, Sun M, Yang H, et al. 2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges[J]. Hepatobiliary Surg Nutr, 2025, 14(1): 66-77.
[2] Wen B, Te L, Bai C, et al. Relative contribution of hepatitis B and C viruses in primary liver cancer in China: a systematic review and meta-analysis[J]. J Infect, 2024, 89(6): 106298.
[3] Liu M, Jiang L, Guan X Y. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update[J]. Protein Cell, 2014, 5(9): 673-691.
[4] Lin C L, Kao J H. Global strategies and actions to eliminate hepatitis B virus infection[J]. Clin Mol Hepatol, 2025, 31(4): 1197-1212.
[5] Iannacone M, Guidotti L G. Immunobiology and pathogenesis of hepatitis B virus infection[J]. Nat Rev Immunol, 2022, 22(1): 19-32.
[6] Zheng H, Xu B, Fan Y, et al. The role of immune regulation in HBV infection and hepatocellular carcinogenesis[J]. Front Immunol, 2025, 16: 1506526.
[7] Tu T, Budzinska M A, Vondran F W R, et al. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles[J]. J Virol, 2018, 92(11).
[8] Wang L, Wang J, Zhao K, et al. The relationship between viral replication and the severity of hepatic necroinflammatory damage changed before HBeAg loss in patients with chronic hepatitis B virus infection[J]. J Clin Transl Hepatol, 2024, 12(4): 381-388.
[9] Jiang B, Wang L, Liu H, et al. Association of HBV serological markers with host antiviral immune response relevant hepatic inflammatory damage in chronic HBV infection[J]. J Med Virol, 2024, 96(4): e29569.
[10] 邢同京, 赵坤宇, 李文涛, 等慢性HBV感染者病毒DNA水平与患者肝组织炎症损伤程度的相关性研究 [J]. 中华肝脏病杂志. 2023, 31(9): 954-960.
[11] Chan H L, Tsang S W, Liew C T, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection[J]. Am J Gastroenterol, 2002, 97(2): 406-412.
[12] Choi W M, Kim G A, Choi J, et al. Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B[J]. J Clin Invest, 2022, 132(10).
[13] Huang D Q, Tran A, Yeh M L, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase[J]. Hepatology, 2023, 78(5): 1558-1568.
[14] Lin C L, Kao J H. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants[J]. Best Pract Res Clin Gastroenterol, 2017, 31(3): 249-255.
[15] Wai C T, Chu C J, Hussain M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C[J]. Hepatology, 2002, 36(6): 1425-1430.
[16] Summers J, Mason W S. Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate[J]. Cell, 1982, 29(2): 403-415.
[17] Lau D T Y, Ganova-Raeva L, Wang J, et al. Precore and basal core promoter hepatitis B virus (HBV) variants are present from a young age and differ across HBV genotypes[J]. Hepatology, 2021, 73(5): 1637-1651.
[18] Lapalus M, Laouenan C, Cardoso A C, et al. Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B[J]. Liver Int, 2015, 35(9): 2082-2089.
[19] Wei F, Zheng Q, Li M, et al. The association between hepatitis B mutants and hepatocellular carcinoma: a meta-analysis[J]. Medicine (Baltimore), 2017, 96(19): e6835.
[20] Yang D, Zou J, Wang L, et al. Letter to the editor: HBeAg expression suppressing/abolishing mutation elevated HBV DNA level in HBeAg-negative patients with chronic HBV infection[J]. Hepatology, 2022, 76(4): E69-E70.
[21] Li G, Yang D, Liu X, et al. Precore mutation enhances viral replication to facilitate persistent infection especially in HBeAg-negative patients[J]. Virol Sin, 2024, 39(2): 319-330.
[22] Yang D, Zou J, Guan G, et al. The A1762T/G1764A mutations enhance HBV replication by alternating viral transcriptome[J]. J Med Virol, 2023, 95(10): e29129.
[23] Akcay I M, Katrinli S, Ozdil K, et al. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies[J]. World J Gastroenterol, 2018, 24(30): 3347-3360.
[24] Zhang T, Huang C J, Chen H T, et al. HLA-DQB1*03:01 and risk of HBV-related HCC[J]. Hepatology, 2026, 83(2): 374-386.
[25] Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians[J]. Nat Genet, 2009, 41(5): 591-595.
[26] Guo X, Zhang Y, Li J, et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population[J]. Hepatology, 2011, 53(2): 422-428.
[27] Deng Y, Li P, Liu W, et al. The genetic polymorphism down-regulating HLA-DRB1 enhancer activity facilitates HBV persistence, evolution and hepatocarcinogenesis in the Chinese Han population[J]. J Viral Hepat, 2020, 27(11): 1150-1161.
[28] Zhang Q, Ji X W, Hou X M, et al. Effect of functional nuclear factor-kappaB genetic polymorphisms on hepatitis B virus persistence and their interactions with viral mutations on the risk of hepatocellular carcinoma[J]. Ann Oncol, 2014, 25(12): 2413-2419.
[29] Guan G, Zhang T, Ning J, et al. Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-α-treated patients with chronic hepatitis B[J]. J Hepatol, 2024, 80(1): 41-52.
[30] Jiang D K, Ma X P, Yu H, et al. Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B[J]. Hepatology, 2015, 62(1): 118-128.
[31] Chen J, Chen H, Mai H, et al. A functional variant of CD40 modulates clearance of hepatitis B virus in hepatocytes via regulation of the ANXA2/CD40/BST2 axis[J]. Hum Mol Genet, 2023, 32(8): 1334-1347.
[32] Golsaz-Shirazi F, Shokri F. Cross talk between hepatitis B virus and innate immunity of hepatocytes[J]. Rev Med Virol, 2022, 32(1): e2256.
[33] Li H, Wang X, Wang Y, et al. Secreted LRPAP1 binds and triggers IFNAR1 degradation to facilitate virus evasion from cellular innate immunity[J]. Signal Transduct Target Ther, 2023, 8(1): 374.
[34] Cho I R, Oh M, Koh S S, et al. Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor[J]. Int J Mol Med, 2012, 29(4): 581-586.
[35] Yang Y, Han Q, Zhang C, et al. Hepatitis B virus antigens impair NK cell function[J]. Int Immunopharmacol, 2016, 38: 291-297.
[36] Op den Brouw M L, Binda R S, van Roosmalen M H, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus[J]. Immunology, 2009, 126(2): 280-289.
[37] Zhao Y, Shao Q, Peng G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment[J]. Cell Mol Immunol, 2020, 17(1): 27-35.
[38] Schurich A, Khanna P, Lopes A R, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection[J]. Hepatology, 2011, 53(5): 1494-1503.
[39] Burton A R, Pallett L J, McCoy L E, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B[J]. J Clin Invest, 2018, 128(10): 4588-4603.
[40] Zhang C, Gao Y, Du C, et al. Hepatitis B-Induced IL8 promotes hepatocellular carcinoma venous metastasis and intrahepatic treg accumulation[J]. Cancer Res, 2021, 81(9): 2386-2398.
[41] Lin N, Yin W, Miller H, et al. The role of regulatory T cells and follicular T helper cells in HBV infection[J]. Front Immunol, 2023, 14: 1169601.

HBV相关肝细胞癌的炎症机制及调控因素研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韩俊妮, 雷耀珍, 耿朝萌, 方乐. SOCS2在肝细胞癌中的表达及其对肝细胞癌增殖、转移和血管生成的影响[J]. 肝脏, 2026, 31(7): 975-979.
[2]	刘伟, 王杰, 陈治西, 刘贤国. MRI纹理参数对肝细胞癌TACE术后早期复发的预测价值[J]. 肝脏, 2026, 31(7): 984-988.
[3]	王鹏, 冯娜欣, 刘泽阳, 庞新. 肝细胞癌组织中E2F8、PKD1表达与临床病理特征、上皮间质转化及预后的关系[J]. 肝脏, 2026, 31(7): 994-999.
[4]	黄珍, 刘娜, 徐光华, 周路路. 替诺福韦与恩替卡韦对乙型肝炎病毒相关肝细胞癌预后的研究进展[J]. 肝脏, 2026, 31(7): 1051-1054.
[5]	周利, 杨松. 酒精摄入加重乙型肝炎病毒诱导肝细胞癌机制的研究进展[J]. 肝脏, 2026, 31(6): 774-778.
[6]	王晓慧, 臧丹, 陈亦扬, 薛云, 李健. 肝细胞癌微血管侵犯病理分级对患者预后不良风险的评估价值[J]. 肝脏, 2026, 31(6): 838-841.
[7]	王建鲁, 孙剑, 申笙. 基于HBeAg与HBsAg定量的HBV相关肝癌风险精准分层[J]. 肝脏, 2026, 31(5): 599-602.
[8]	冒慧, 余姣. 肝细胞癌筛查中甲胎蛋白阈值的再思考[J]. 肝脏, 2026, 31(5): 602-605.
[9]	许丹青, 木唤, 张映媛, 李文彦, 撒采芬, 刘立, 李卫昆. 病毒性肝炎肝硬化失代偿患者再代偿对预后的影响[J]. 肝脏, 2026, 31(5): 619-624.
[10]	田振英, 陈妍. 郑州市23 069例磁微粒化学发光法HBsAg和抗-HBs检测结果分析[J]. 肝脏, 2026, 31(5): 643-647.
[11]	张猛, 钱小建. CT定量参数联合血清CA199、CEA、VEGF-C水平诊断肝局灶性结节增生与肝细胞癌的价值[J]. 肝脏, 2026, 31(5): 653-657.
[12]	刘若男, 吴旭, 李嘉文, 苏比努尔·库尔班, 王晓忠. 肝细胞癌相关预测模型的临床应用进展[J]. 肝脏, 2026, 31(5): 744-747.
[13]	张林, 严友德, 张振江. CALLY指数在肝脏疾病中的临床应用与研究进展[J]. 肝脏, 2026, 31(5): 748-751.
[14]	梁欣, 李超, 吴寒, 王明达, 杜祖超, 杨田. 磷酸化蛋白质组学在肝细胞癌分子分型中的应用与研究进展[J]. 肝脏, 2026, 31(4): 469-473.
[15]	零芳蓬, 陈雪梅, 范冰凌, 蓝诗雨, 李小婷, 韦美料, 韦来安, 江建宁, 苏明华. 白球比联合FIB-4对慢性HBV感染者肝纤维化程度的预测价值[J]. 肝脏, 2026, 31(4): 503-507.